| Hemophilia B
Alprolix vs BeneFix
Side-by-side clinical, coverage, and cost comparison for hemophilia b.Deep comparison between: Alprolix vs Benefix with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsBenefix has a higher rate of injection site reactions vs Alprolix based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Benefix but not Alprolix, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Alprolix
Benefix
At A Glance
IV infusion
Weekly or every 10 days
Recombinant Factor IX replacement
IV infusion
Once weekly
Recombinant factor IX
Indications
- Hemophilia B
- Hemophilia B
Dosing
Hemophilia B - On-demand (minor/moderate bleeding) Target FIX level 30-60 IU/dL by IV infusion; repeat every 48 hours if further bleeding is present.
Hemophilia B - On-demand (major bleeding) Target FIX level 80-100 IU/dL by IV infusion; consider repeat dose after 6-10 hours, then every 24 hours for the first 3 days, then every 48 hours or longer until bleeding stops and healing is achieved.
Hemophilia B - Perioperative (minor surgery) Target FIX level 50-80 IU/dL by IV infusion; single infusion may be sufficient; repeat every 24-48 hours as needed until bleeding stops and healing is achieved.
Hemophilia B - Perioperative (major surgery) Target FIX level 60-100 IU/dL by IV infusion; consider repeat dose after 6-10 hours, then every 24 hours for the first 3 days, then every 48 hours or longer until bleeding stops and healing is achieved.
Hemophilia B - Routine prophylaxis 50 IU/kg IV once weekly or 100 IU/kg IV once every 10 days for adults and adolescents >=12 years; adjust dose and frequency based on individual response, with more frequent or higher doses possibly needed in children.
Hemophilia B - On-demand and Perioperative Management IV infusion; dose (IU) = body weight (kg) x desired factor IX increase (IU/dL) x reciprocal of observed recovery; minor hemorrhage: target 20-30 IU/dL every 12-24 hours for 1-2 days; moderate: 25-50 IU/dL every 12-24 hours for 2-7 days; major/surgery: 50-100 IU/dL every 12-24 hours for 7-10 days.
Hemophilia B - Routine Prophylaxis 100 IU/kg IV infusion once weekly; children under 12 years may require more frequent or higher doses.
Contraindications
- Known history of hypersensitivity reactions, including anaphylaxis, to ALPROLIX or its excipients (sucrose, mannitol, sodium chloride, L-histidine, polysorbate 20)
- Life-threatening immediate hypersensitivity reactions, including anaphylaxis, to BeneFIX or its components, including hamster protein
Adverse Reactions
Most common (>=1%) in previously treated patients Headache, oral paresthesia, obstructive uropathy
Most common (>=1%) in previously untreated patients Injection site erythema, hypersensitivity, Factor IX inhibition
Postmarketing Factor IX inhibitor development, hypersensitivity including anaphylaxis
Most common (>5%) Fever, cough, headache, dizziness, nausea, injection site reaction, injection site pain, rash, hives
Serious Systemic hypersensitivity reactions including bronchospasm, hypotension, and anaphylaxis; high-titer inhibitor development requiring alternative treatments to factor IX replacement therapy
Postmarketing Anaphylaxis, angioedema, dyspnea, hypotension, thrombosis, inadequate factor IX recovery, inhibitor development, SVC syndrome in critically ill neonates (continuous infusion), peripheral thrombophlebitis, DVT
Pharmacology
ALPROLIX is a recombinant Factor IX Fc fusion protein that temporarily replaces the missing coagulation Factor IX needed for effective hemostasis; the Fc region binds to the neonatal Fc receptor (FcRn), recycling the protein back into circulation and prolonging its plasma half-life.
Recombinant coagulation factor IX that temporarily replaces missing factor IX needed for effective hemostasis, normalizing the activated partial thromboplastin time (aPTT) and correcting the coagulation defect in patients with hemophilia B.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Alprolix
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (0/12)
Benefix
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Alprolix
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Benefix
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Alprolix
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (0/3)
Benefix
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAccessia Health: Inherited and Acquired Factor Deficiencies - Private Insurance: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAccessia Health: Inherited and Acquired Factor Deficiencies - Private Insurance: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
AlprolixView full Alprolix profile
BenefixView full Benefix profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.